

HIGHLIGHTS

Annual Meetings of the WHO-coordinated Global Poliomyelitis Laboratory Network 12-15 March 2018 - Geneva, Switzerland

Two meetings of the Global Poliomyelitis Laboratory Network (GPLN) members have been held in WHO Headquarters from 12-15 March:

1. Ad Hoc Small Working Group (SWG) of the Global Poliomyelitis Laboratory Network, 12-13 March 2018

Members of the SWG discussed progress with development of new methodologies, approaches and all issues relevant to improvement of polio diagnostics in the context of Polio Eradication and Endgame Strategic Plan 2013–2018 and the Polio Post Certification Strategic Plan.

2. The 24th Informal Consultation of the Global Poliomyelitis Laboratory Network, 14-15 March 2018

At the annual meeting of the GPLN, participants from Global Specialized, Regional Reference Laboratories, National laboratories and Global Polio Eradication Initiative (GPEI) partners have gathered and discussed:


- recent advances in global polio eradication with emphasis on laboratory support to the programme;
- overall performance of the GPLN and report on the GPLN's quality assurance programme and capacity building;
- alignment of polio diagnostics with the programme needs; and
- implementation of the Global Environmental Surveillance Expansion Plan with recommendations to the GPLN and field surveillance officers.



CONTACT US

Expanded Programme on Immunization
Regional Office for the Western Pacific
World Health Organization
P.O. Box 2932, 1000 Manila, Philippines
Phone: +63 2 5288001
Fax: +63 2 5211036, 5260279
Email: wproepidata@who.int
Web: www.wpro.who.int/immunization

Chart 1. Non-polio AFP rate (per 100 000 persons < 15 years of age), 2016–2018*



* AFP rate annualized as of week 12

Chart 2. Adequate specimen collection rate, 2016–2018




Chart 3. Percentage of reported AFP cases by number of polio vaccination doses, 2018





Chart 4. Percentage of reported AFP cases with pending classification > 90 days after onset, 2018



Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People's Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam).

Table 1A. Classification of AFP cases with onset in 2017 and key surveillance indicators

| Country/area | 2016 | 2017 | | | | | | | | | | | | |
|------------------------------------|----------------------|--|----------------------|---------------------------|-----------------------------------|------------------|-----------------------|------------|------------------------------|--------------------|--|--|---------------------------------|-------------------------------------|
| | Total reported cases | Annual expected cases <15 years of age | Total reported cases | Classification | | | | | | Indicators | | | Latest report date ⁴ | Days since last report ⁵ |
| | | | | Confirmed wild poliovirus | Vaccine-derived poliovirus (VDPV) | Polio-compatible | Discarded (Non-polio) | Pending | | Non-polio AFP rate | % with adequate specimens ² | % investigated ≤ 2 days of notification ³ | | |
| | | | | | | | | Total | > 90 days ¹ # (%) | | | | | ≥ 1 |
| Australia | 62 | 45 | 59 | 0 | 0 | 1 | 58 | 0 | 0 (0.0%) | 1.31 | 37% | 97% | 19-Mar-18 | - |
| Brunei Darrusalam | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 (0.0%) | 1.00 | 0% | 100% | 09-Jan-18 | - |
| Cambodia | 51 | 45 | 57 | 0 | 0 | 0 | 57 | 0 | 0 (0.0%) | 1.27 | 91% | 95% | 07-Feb-18 | - |
| China | 5691 | 2256 | 5352 | 0 | 2 | 0 | 5060 | 290 | 254 (4.7%) | 2.37 | 93% | 100% | 21-Mar-18 | 5 |
| China, Hong Kong SAR | 10 | 8 | 15 | 0 | 0 | 0 | 15 | 0 | 0 (0.0%) | 1.88 | 80% | 100% | 01-Mar-18 | - |
| China, Macao SAR | 1 | 1 | 2 | 0 | 0 | 0 | 2 | 0 | 0 (0.0%) | 2.00 | 50% | 100% | 18-Jan-18 | - |
| Japan | - | 161 | - | - | - | - | - | - | - | - | - | - | - | - |
| Lao People's Democratic Republic | 133 | 21 | 103 | 0 | 0 | 0 | 103 | 0 | 0 (0.0%) | 4.90 | 73% | 73% | 27-Feb-18 | - |
| Malaysia | 143 | 77 | 154 | 0 | 0 | 0 | 154 | 0 | 0 (0.0%) | 2.00 | 82% | 90% | 06-Mar-18 | - |
| Mongolia | 7 | 9 | 6 | 0 | 0 | 0 | 6 | 0 | 0 (0.0%) | 0.67 | 83% | 100% | 11-Jan-18 | - |
| New Zealand | 12 | 9 | 13 | 0 | 0 | 0 | 13 | 0 | 0 (0.0%) | 1.44 | 38% | 100% | 02-Mar-18 | - |
| Papua New Guinea | 23 | 31 | 26 | 0 | 0 | 0 | 26 | 0 | 0 (0.0%) | 0.84 | 46% | 100% | 28-Feb-18 | - |
| Philippines | 417 | 400 | 463 | 0 | 0 | 0 | 463 | 0 | 0 (0.0%) | 1.16 | 68% | 97% | 26-Mar-18 | - |
| Republic of Korea | 70 | 68 | 68 | 0 | 0 | 0 | 68 | 0 | 0 (0.0%) | 1.00 | 94% | 100% | 12-Mar-18 | - |
| Singapore | 7 | 6 | 7 | 0 | 0 | 0 | 7 | 0 | 0 (0.0%) | 1.17 | 86% | 100% | 07-Feb-18 | - |
| Viet Nam | 382 | 234 | 385 | 0 | 0 | 0 | 384 | 1 | 1 (0.3%) | 1.65 | 94% | 89% | 16-Mar-18 | 10 |
| Pacific island countries and areas | 20 | 11 | 16 | 0 | 0 | 0 | 13 | 3 | 1 (6.3%) | 1.45 | 63% | 100% | 20-Feb-18 | 34 |
| Total | 7030 | 3383 | 6727 | 0 | 2 | 1 | 6430 | 294 | 256 (3.8%) | 1.99 | 90% | 98% | | |

1. Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report
2. Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis
3. Percentage of reported cases investigated within two days of notification
4. Report date is fixed as soon as all cases for the year have been classified
5. Countries are expected to submit data at least once per month to WPRO

| | |
|---|--|
| | Reached or surpass target |
| | Nearly reached target 0.5-0.99 for non-polio AFP rate; 60-79% for other indicators |
| | Substantially below target |

Table 1B. Classification of AFP cases with onset in 2018 and key surveillance indicators

| Country/area | 2017 | | 2018 | | | | | | | | | | | |
|------------------------------------|----------------------|--|----------------------|---------------------------|-----------------------------------|------------------|-----------------------|------------|------------------------------|---------------------------------|--|--|--------------------|-------------------------------------|
| | Total reported cases | Annual expected cases <15 years of age | Total reported cases | Classification | | | | | | Indicators | | | Latest report date | Days since last report ⁵ |
| | | | | Confirmed wild poliovirus | Vaccine-derived poliovirus (VDPV) | Polio-compatible | Discarded (Non-polio) | Pending | | Non-polio AFP rate ² | % with adequate specimens ³ | % investigated ≤ 2 days of notification ⁴ | | |
| | | | | | | | | Total | > 90 days ¹ # (%) | | | | | |
| ≥ 1 | ≥ 80% | ≥ 80% | ≤ 30 | | | | | | | | | | | |
| Australia | 59 | 46 | 8 | 0 | 0 | 0 | 0 | 8 | 1 (12.5%) | 0.75 | 50% | 88% | 26-Mar-18 | 0 |
| Brunei Darussalam | 1 | 1 | 0 | - | - | - | - | - | - | - | - | - | 15-Mar-18 | 11 |
| Cambodia | 57 | 44 | 2 | 0 | 0 | 0 | 2 | 0 | 0 (0.0%) | 0.20 | 0% | 50% | 07-Feb-18 | 47 |
| China | 5352 | 2256 | 630 | 0 | 0 | 0 | 98 | 532 | 0 (0.0%) | 1.21 | 93% | 99% | 21-Mar-18 | 5 |
| China, Hong Kong SAR | 15 | 9 | 0 | - | - | - | - | - | - | - | - | - | 01-Mar-18 | 25 |
| China, Macao SAR | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 (0.0%) | 4.33 | 100% | 100% | 13-Mar-18 | 13 |
| Japan | - | 161 | - | - | - | - | - | - | - | - | - | - | - | - |
| Lao People's Democratic Republic | 103 | 21 | 13 | 0 | 0 | 0 | 7 | 6 | 0 (0.0%) | 2.68 | 85% | 54% | 27-Feb-18 | 27 |
| Malaysia | 154 | 77 | 22 | 0 | 0 | 0 | 5 | 17 | 0 (0.0%) | 1.24 | 77% | 55% | 20-Mar-18 | 6 |
| Mongolia | 6 | 9 | 1 | 0 | 0 | 0 | 0 | 1 | 0 (0.0%) | 0.48 | 100% | 100% | 05-Mar-18 | 21 |
| New Zealand | 13 | 9 | 0 | - | - | - | - | - | - | - | - | - | 02-Mar-18 | 24 |
| Papua New Guinea | 26 | 34 | 3 | 0 | 0 | 0 | 0 | 3 | 0 (0.0%) | 0.38 | 33% | 67% | 13-Mar-18 | 13 |
| Philippines | 463 | 338 | 46 | 0 | 0 | 0 | 22 | 24 | 2 (4.3%) | 0.59 | 57% | 96% | 20-Mar-18 | 6 |
| Republic of Korea | 68 | 67 | 11 | 0 | 0 | 0 | 0 | 11 | 0 (0.0%) | 0.71 | 91% | 100% | 12-Mar-18 | 14 |
| Singapore | 7 | 6 | 0 | - | - | - | - | - | - | - | - | - | 09-Mar-18 | 17 |
| Viet Nam | 385 | 234 | 11 | 0 | 0 | 0 | 3 | 8 | 0 (0.0%) | 0.20 | 100% | 82% | 16-Mar-18 | 10 |
| Pacific island countries and areas | 16 | 11 | 0 | - | - | - | - | - | - | - | - | - | 20-Feb-18 | 34 |
| Total | 6727 | 3324 | 748 | 0 | 0 | 0 | 138 | 610 | 3 (0.4%) | 0.98 | 89% | 96% | | |

1. Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report
2. Annualized non-polio AFP rate per 100 000 population under 15 years of age
3. Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis
4. Percentage of reported cases investigated within two days of notification
5. Countries are expected to submit data at least once per month to WPRO

| | |
|--|--|
| | Reached or surpass target |
| | Nearly reached target 0.5-0.99 for non-polio AFP rate; 60-79% for other indicators |
| | Substantially below target |

Table 2A. Laboratory investigation of stool samples from AFP cases with onset in 2017 and key laboratory indicators

| Country/area | Polio laboratory | Total no. of AFP cases with specimens | Results of virus isolation for AFP cases | | | | | | | | | | Intratype differentiation/ Sequencing laboratory ¹ | No. of isolates received | Results of intratype differentiation (ITD)/sequencing for virus isolates | | | | | | | | | | | | | | | |
|------------------------------------|------------------|---------------------------------------|--|----------------------|------------|-------------|-------------------|-------------------|------------------------------|-----------|-------------------------------|--------------------|---|--------------------------|--|----------|----------|----------|----------|-----------|-----------|-----------|----------|-------------------|-------------|-------------------------------|--|----------|------------|------|
| | | | L20B positive | L20B positive + NPEV | NPEV only | Negative | Pending ≤ 14 days | Pending > 14 days | % results reported ≤ 14 days | | % specimens positive for NPEV | Latest report date | | | Type 1 | | | Type 2 | | | Type 3 | | | NPEV ² | Pending ITD | Discordant pending sequencing | % ITD results reported ≤ 7 days of receipt | | | |
| | | | | | | | | | ≥ 80% | | | | | | Wild | Sabin | VDPV | Wild | Sabin | VDPV | Wild | Sabin | VDPV | | | | | | | |
| | | | | | | | | | ≥ 80% | ≥ 80% | | | | | | | | | | | | | | | | | | | | |
| Australia | VIDRL | 44 | 0 | 0 | 4 | 40 | 0 | 0 | 95% | 10% | 08-Feb-18 | VIDRL | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| Brunei Darussalam | VIDRL | 0 | - | - | - | - | - | - | - | - | 08-Feb-18 | VIDRL | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cambodia | NIID | 57 | 0 | 0 | 6 | 51 | 0 | 0 | 96% | 9% | 26-Jan-18 | NIID | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China (total) | | 5283 | 48 | 0 | 347 | 4880 | 0 | 8 | 96% | 6% | 21-Mar-18 | | 130 | 0 | 40 | 0 | 0 | 0 | 0 | 64 | 18 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 99% | |
| China, Anhui | Prov. Lab | 302 | 3 | 0 | 13 | 286 | 0 | 0 | 100% | 3% | | Prov. Lab/CCDC | 8 | 0 | 6 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Beijing | Prov. Lab | 33 | 1 | 0 | 0 | 32 | 0 | 0 | 97% | 0% | | Prov. Lab/CCDC | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Chongqing | Prov. Lab | 80 | 0 | 0 | 2 | 78 | 0 | 0 | 93% | 2% | | Prov. Lab/CCDC | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Fujian | Prov. Lab | 179 | 1 | 0 | 11 | 167 | 0 | 0 | 95% | 5% | | Prov. Lab/CCDC | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Gansu | Prov. Lab | 101 | 0 | 0 | 2 | 99 | 0 | 0 | 99% | 1% | | Prov. Lab/CCDC | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Guangdong | Prov. Lab | 399 | 4 | 0 | 33 | 362 | 0 | 0 | 94% | 7% | | Prov. Lab/CCDC | 12 | 0 | 6 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Guangxi | Prov. Lab | 269 | 5 | 0 | 33 | 231 | 0 | 0 | 97% | 11% | | Prov. Lab/CCDC | 10 | 0 | 4 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Guizhou | Prov. Lab | 193 | 0 | 0 | 15 | 178 | 0 | 0 | 97% | 7% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Hebei | Prov. Lab | 282 | 4 | 0 | 28 | 250 | 0 | 0 | 99% | 8% | | Prov. Lab/CCDC | 7 | 0 | 4 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Heilongjiang | Prov. Lab | 106 | 1 | 0 | 5 | 100 | 0 | 0 | 100% | 5% | | Prov. Lab/CCDC | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Henan | Prov. Lab | 517 | 8 | 0 | 58 | 451 | 0 | 0 | 91% | 9% | | Prov. Lab/CCDC | 21 | 0 | 2 | 0 | 0 | 0 | 0 | 14 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Hubei | Prov. Lab | 195 | 0 | 0 | 21 | 174 | 0 | 0 | 97% | 10% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Hunan | Prov. Lab | 265 | 1 | 0 | 18 | 246 | 0 | 0 | 99% | 6% | | Prov. Lab/CCDC | 4 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Jiangsu | Prov. Lab | 229 | 4 | 0 | 3 | 222 | 0 | 0 | 100% | 1% | | Prov. Lab/CCDC | 8 | 0 | 2 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Jiangxi | Prov. Lab | 163 | 1 | 0 | 16 | 146 | 0 | 0 | 95% | 8% | | Prov. Lab/CCDC | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Jilin | Prov. Lab | 60 | 1 | 0 | 6 | 53 | 0 | 0 | 100% | 8% | | Prov. Lab/CCDC | 4 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50% |
| China, Neimongol | Prov. Lab | 100 | 2 | 0 | 1 | 97 | 0 | 0 | 99% | 1% | | Prov. Lab/CCDC | 5 | 0 | 3 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Ningxia | Prov. Lab | 19 | 0 | 0 | 2 | 17 | 0 | 0 | 95% | 11% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Shaanxi | Prov. Lab | 111 | 1 | 0 | 2 | 103 | 0 | 5 | 92% | 2% | | Prov. Lab/CCDC | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Shandong | Prov. Lab | 366 | 5 | 0 | 9 | 352 | 0 | 0 | 95% | 2% | | Prov. Lab/CCDC | 25 | 0 | 1 | 0 | 0 | 0 | 0 | 7 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Shanghai | Prov. Lab | 37 | 0 | 0 | 0 | 37 | 0 | 0 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Shanxi | Prov. Lab | 157 | 0 | 0 | 6 | 151 | 0 | 0 | 94% | 3% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Sichuan | Prov. Lab | 364 | 0 | 0 | 21 | 343 | 0 | 0 | 96% | 5% | | Prov. Lab/CCDC | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Tianjin | Prov. Lab | 30 | 0 | 0 | 0 | 30 | 0 | 0 | 98% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Xinjiang | Prov. Lab | 151 | 4 | 0 | 10 | 136 | 0 | 1 | 93% | 6% | | Prov. Lab/CCDC | 8 | 0 | 5 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Yunnan | Prov. Lab | 245 | 1 | 0 | 18 | 225 | 0 | 1 | 92% | 6% | | Prov. Lab/CCDC | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Zhejiang | Prov. Lab | 173 | 1 | 0 | 7 | 165 | 0 | 0 | 99% | 3% | | Prov. Lab/CCDC | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| China, Hainan | Prov. Lab | 31 | 0 | 0 | 3 | 28 | 0 | 0 | 93% | 8% | | CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Liaoning | Prov. Lab | 97 | 0 | 0 | 3 | 93 | 0 | 1 | 99% | 2% | | CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Qinghai | Prov. Lab | 21 | 0 | 0 | 1 | 20 | 0 | 0 | 100% | 5% | | CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Tibet | Prov. Lab | 8 | 0 | 0 | 0 | 8 | 0 | 0 | 63% | 0% | | CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Hong Kong SAR | PHLC | 15 | 0 | 0 | 0 | 15 | 0 | 0 | 98% | 0% | 22-Jan-18 | PHLC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Macao SAR | PHLC | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 100% | 0% | 22-Jan-18 | PHLC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Japan | NIID | - | - | - | - | - | - | - | - | - | - | NIID | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Lao People's Democratic Republic | NIID | 144 | 1 | 1 | 15 | 127 | 0 | 0 | 96% | 10% | 29-Jan-18 | NIID | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| Malaysia | IMR | 182 | 0 | 0 | 9 | 173 | 0 | 0 | 98% | 5% | 09-Feb-18 | IMR | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Mongolia | PHI | 7 | 0 | 0 | 0 | 7 | 0 | 0 | 100% | 0% | 27-Feb-18 | NIID | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| New Zealand | IESR | 9 | 0 | 0 | 0 | 9 | 0 | 0 | 100% | 0% | 23-Jan-18 | IESR | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Papua New Guinea | VIDRL | 26 | 0 | 0 | 8 | 18 | 0 | 0 | 100% | 22% | 08-Feb-18 | VIDRL | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Philippines | RITM | 478 | 6 | 0 | 27 | 442 | 3 | 0 | 97% | 4% | 13-Mar-18 | RITM | 15 | 0 | 4 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| Republic of Korea | NIH | 68 | 0 | 0 | 4 | 64 | 0 | 0 | 97% | 4% | 09-Feb-18 | NIH | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Singapore | SGH | 7 | 0 | 0 | 0 | 7 | 0 | 0 | 100% | 0% | 15-Feb-18 | SGH | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Viet Nam (North) | NIHE | 177 | 1 | 0 | 29 | 147 | 0 | 0 | 100% | 14% | 25-Jan-18 | NIHE | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% |
| Viet Nam (South) | PI | 194 | 0 | 0 | 34 | 160 | 0 | 0 | 100% | 18% | 21-Feb-18 | PI | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pacific island countries and areas | VIDRL | 16 | 0 | 0 | 5 | 11 | 0 | 0 | 100% | 26% | 08-Feb-18 | VIDRL | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total | | 6709 | 56 | 1 | 488 | 6153 | 3 | 8 | 95% | 6% | | | 151 | 0 | 44 | 0 | 0 | 0 | 0 | 79 | 18 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 99% | |

1. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)

2. NPEV growing in L20B cells

Table 2B. Laboratory investigation of stool samples from AFP cases with onset in 2018 and key laboratory indicators

| Country/area | Poli laboratory | Total no. of AFP cases with specimens | Results of virus isolation for AFP cases | | | | | | | | | | Intratyptic differentiation/ Sequencing laboratory ¹ | No. of isolates received | Results of intratyptic differentiation (ITD)/sequencing for virus isolates | | | | | | | | | | | | | | | |
|------------------------------------|-----------------|---------------------------------------|--|----------------------|-----------|------------|-------------------|-------------------|------------------------------|-------------------------------|--------------------|----------------|---|--------------------------|--|----------|----------|----------|----------|----------|-------------------|-------------|-------------------------------|--|----------|----------|----------|----------|-------------|------|
| | | | L20B positive | L20B positive + NPEV | NPEV only | Negative | Pending ≤ 14 days | Pending > 14 days | % results reported ≤ 14 days | % specimens positive for NPEV | Latest report date | Type 1 | | | Type 2 | | | Type 3 | | | NPEV ² | Pending ITD | Discordant pending sequencing | % ITD results reported ≤ 7 days of receipt | | | | | | |
| | | | | | | | | | | | | Wild | | | Sabin | VDPV | Wild | Sabin | VDPV | Wild | | | | | Sabin | VDPV | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Australia | VIDRL | 8 | 0 | 0 | 0 | 5 | 3 | 0 | 100% | 0% | 28-Feb-18 | VIDRL | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Brunei Darussalam | VIDRL | 0 | - | - | - | - | - | - | - | - | 28-Feb-18 | VIDRL | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cambodia | NIID | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 100% | 25% | 07-Feb-18 | NIID | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China (total) | | 618 | 2 | 0 | 17 | 557 | 2 | 40 | 96% | 3% | 21-Mar-18 | | 5 | 0 | 2 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Anhui | Prov. Lab | 24 | 0 | 0 | 0 | 24 | 0 | 0 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Beijing | Prov. Lab | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Chongqing | Prov. Lab | 11 | 0 | 0 | 0 | 11 | 0 | 0 | 86% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Fujian | Prov. Lab | 30 | 1 | 0 | 0 | 26 | 0 | 3 | 100% | 0% | | Prov. Lab/CCDC | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |
| China, Gansu | Prov. Lab | 6 | 0 | 0 | 0 | 5 | 0 | 1 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Guangdong | Prov. Lab | 57 | 0 | 0 | 0 | 56 | 0 | 1 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Guangxi | Prov. Lab | 32 | 0 | 0 | 1 | 29 | 0 | 2 | 93% | 3% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Guizhou | Prov. Lab | 27 | 0 | 0 | 0 | 25 | 0 | 2 | 96% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Hebei | Prov. Lab | 40 | 0 | 0 | 6 | 32 | 0 | 2 | 100% | 13% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Heilongjiang | Prov. Lab | 11 | 0 | 0 | 1 | 10 | 0 | 0 | 100% | 9% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Henan | Prov. Lab | 58 | 0 | 0 | 1 | 57 | 0 | 0 | 100% | 1% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Hubei | Prov. Lab | 14 | 0 | 0 | 1 | 13 | 0 | 0 | 93% | 7% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Hunan | Prov. Lab | 12 | 0 | 0 | 1 | 11 | 0 | 0 | 83% | 4% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Jiangsu | Prov. Lab | 12 | 0 | 0 | 0 | 11 | 0 | 1 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Jiangxi | Prov. Lab | 17 | 0 | 0 | 0 | 13 | 0 | 4 | 96% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Jilin | Prov. Lab | 13 | 1 | 0 | 0 | 9 | 0 | 3 | 100% | 0% | | Prov. Lab/CCDC | 4 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | 100% |
| China, Neimongol | Prov. Lab | 10 | 0 | 0 | 1 | 8 | 0 | 1 | 100% | 11% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Ningxia | Prov. Lab | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Shaanxi | Prov. Lab | 20 | 0 | 0 | 0 | 18 | 0 | 2 | 94% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Shandong | Prov. Lab | 51 | 0 | 0 | 0 | 49 | 2 | 0 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Shanghai | Prov. Lab | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Shanxi | Prov. Lab | 27 | 0 | 0 | 0 | 27 | 0 | 0 | 89% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Sichuan | Prov. Lab | 44 | 0 | 0 | 1 | 30 | 0 | 13 | 95% | 2% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Tianjin | Prov. Lab | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Xinjiang | Prov. Lab | 12 | 0 | 0 | 1 | 11 | 0 | 0 | 92% | 8% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Yunnan | Prov. Lab | 41 | 0 | 0 | 3 | 35 | 0 | 3 | 84% | 8% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Zhejiang | Prov. Lab | 20 | 0 | 0 | 0 | 20 | 0 | 0 | 100% | 0% | | Prov. Lab/CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Hainan | Prov. Lab | 5 | 0 | 0 | 0 | 5 | 0 | 0 | 100% | 0% | | CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Liaoning | Prov. Lab | 7 | 0 | 0 | 0 | 7 | 0 | 0 | 100% | 0% | | CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Qinghai | Prov. Lab | 4 | 0 | 0 | 0 | 3 | 0 | 1 | 100% | 0% | | CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Tibet | Prov. Lab | 1 | 0 | 0 | 0 | 0 | 0 | 1 | - | - | | CCDC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Hong Kong SAR | PHLC | 0 | - | - | - | - | - | - | - | - | 08-Mar-18 | PHLC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| China, Macao SAR | PHLC | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 100% | 0% | 08-Mar-18 | PHLC | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Japan | NIID | - | - | - | - | - | - | - | - | - | - | NIID | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Lao People's Democratic Republic | NIID | 24 | 0 | 0 | 3 | 21 | 0 | 0 | 98% | 9% | 22-Mar-18 | NIID | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Malaysia | IMR | 13 | 0 | 0 | 1 | 12 | 0 | 0 | 92% | 8% | 07-Mar-18 | IMR | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Mongolia | PHI | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 100% | 100% | 23-Mar-18 | NIID | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| New Zealand | IESR | 1 | 0 | 0 | 0 | 0 | 1 | 0 | - | - | 21-Mar-18 | IESR | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Papua New Guinea | VIDRL | 2 | 0 | 0 | 0 | 0 | 2 | 0 | - | - | 28-Feb-18 | VIDRL | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Philippines | RITM | 70 | 0 | 0 | 3 | 57 | 10 | 0 | 98% | 3% | 20-Mar-18 | RITM | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Republic of Korea | NIH | 11 | 0 | 0 | 0 | 7 | 4 | 0 | 100% | 0% | 12-Mar-18 | NIH | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Singapore | SGH | 0 | - | - | - | - | - | - | - | - | 23-Mar-18 | SGH | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Viet Nam (North) | NIHE | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 100% | 0% | 28-Feb-18 | NIHE | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Viet Nam (South) | PI | 10 | 0 | 0 | 1 | 7 | 2 | 0 | 100% | 13% | 14-Mar-18 | PI | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pacific island countries and areas | VIDRL | 0 | - | - | - | - | - | - | - | - | 28-Feb-18 | VIDRL | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total | | 764 | 2 | 0 | 27 | 671 | 24 | 40 | 97% | 3% | | | 5 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100% | |

1. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)
 2. NPEV growing in L20B cells

Table 3. Laboratory confirmation of polio isolates from environmental samples in 2017–2018 ¹

| Country/area | Intratyptic differentiation lab ² | 2017 | | | | | | | | | | | | | 2018 | | | | | | | | | | | | | | | |
|---------------------|--|-----------------------------------|---|----------------|------------|----------|----------|----------|----------|----------|------------|----------|-------------|-------------|-------------------------------|-----------------------------------|---|----------------|----------|----------|----------|----------|----------|----------|-----------|----------|-----------|-------------|-------------------------------|---|
| | | Total number of samples processed | Total number of samples with polio isolates | Polio isolates | | | | | | | | | NPEV | Pending ITD | Discordant pending sequencing | Total number of samples processed | Total number of samples with polio isolates | Polio isolates | | | | | | | | | NPEV | Pending ITD | Discordant pending sequencing | |
| | | | | Type 1 | | | Type 2 | | | Type 3 | | | | | | | | Type 1 | | | Type 2 | | | Type 3 | | | | | | |
| | | | | Wild | Sabin | VDPV | Wild | Sabin | VDPV | Wild | Sabin | VDPV | | | | | | Wild | Sabin | VDPV | Wild | Sabin | VDPV | Wild | Sabin | VDPV | | | | |
| Australia | VIDRL | 6 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 8 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| China (total) | | 320 | 182 | 0 | 212 | 0 | 0 | 0 | 0 | 0 | 633 | 0 | 1130 | 0 | 0 | 11 | 10 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 33 | 0 | 55 | 0 | 0 | |
| China, Fujian | Prov. Lab/CCDC | 53 | 22 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 42 | 0 | 331 | 0 | 0 | 8 | 7 | 0 | 1 | 0 | 0 | 0 | 0 | 18 | 0 | 50 | 0 | 0 | | |
| China, Gansu | Prov. Lab/CCDC | 10 | 8 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 27 | 0 | 12 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | | |
| China, Guangdong | Prov. Lab/CCDC | 48 | 39 | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 87 | 0 | 108 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | | |
| China, Guangxi | Prov. Lab/CCDC | 36 | 20 | 0 | 22 | 0 | 0 | 0 | 0 | 0 | 36 | 0 | 94 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | | | |
| China, Heilongjiang | Prov. Lab/CCDC | 42 | 16 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 110 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | | | |
| China, Shandong | Prov. Lab/CCDC | 45 | 27 | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 88 | 0 | 258 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | | | |
| China, Shanghai | Prov. Lab/CCDC | 22 | 16 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 54 | 0 | 45 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | | | | |
| China, Xinjiang | Prov. Lab/CCDC | 36 | 34 | 0 | 108 | 0 | 0 | 0 | 0 | 0 | 267 | 0 | 115 | 0 | 0 | 3 | 3 | 0 | 3 | 0 | 0 | 0 | 0 | 15 | 0 | 5 | 0 | 0 | | |
| China, Yunnan | Prov. Lab/CCDC | 28 | 0 | - | - | - | - | - | - | - | - | - | 57 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | | | |
| Malaysia | IMR | 24 | 0 | - | - | - | - | - | - | - | - | - | 22 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | | | |
| Philippines | RITM | 40 | 8 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 21 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | | |
| Total | | 390 | 192 | 0 | 213 | 0 | 0 | 0 | 1 | 0 | 641 | 0 | 1177 | 0 | 0 | 29 | 12 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 33 | 0 | 62 | 0 | 0 | |

1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory.

2. CCDC (Chinese Center for Disease Control and Prevention, China); IMR (Institute of Medical Research, Malaysia); RITM (Research Institute for Tropical Medicine, Philippines); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)

Table 4. Vaccine-derived poliovirus¹ identified from laboratory testing², 2000–2018

| Country/area | 2000–2009 ³ | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|----------------------------------|------------------------|--|--|---|---|--|--|-----------------------------|---|------|
| Australia | | | | | | | | | aVDPV2 (1 env) | |
| Cambodia | 2006 - 1 Total - 2 | | | | | | | | | |
| China | 2009 - 1 Total - 27 | aVDPV2 (3 AFP + 1 contact + 1 non-AFP) aVDPV3 (1 AFP + 1 non-AFP) | aVDPV1 (1 AFP) aVDPV2 (2 AFP + 1 contact) cVDPV2 (2 AFP) iVDPV2 (1 AFP + 1 non-AFP) iVDPV3 (1 AFP) | aVDPV1 (1 AFP) aVDPV2 (2 AFP) cVDPV2 (2 AFP + 1 contact) iVDPV2 + iVDPV3 (1 AFP) | aVDPV2 (1 non-AFP) iVDPV2 + iVDPV3 (1 AFP) | aVDPV1 (1 non-AFP) aVDPV2 (2 AFP) iVDPV3 (1 AFP) | aVDPV1 (1 AFP) aVDPV2 (1 AFP) iVDPV2 (1 AFP) aVDPV2 (1 env) | aVDPV3 (1 AFP) | aVDPV3 (1 AFP) iVDPV3 (1 AFP) ⁴ | |
| China, Hong Kong SAR | 2005 - 3 | | | | | | | | | |
| Japan | 2005 - 1 Total - 2 | | | | | | | | | |
| Lao People's Democratic Republic | 2004 - 3 | | | | | | cVDPV1 (8 AFP + 21 contacts) | cVDPV1 (3 AFP + 4 contacts) | | |
| Mongolia | 2003 - 1 | | | | | | | | | |
| Philippines | 2001 - 3 | | | | | aVDPV2 (1 AFP) | | | | |
| Viet Nam | | | | aVDPV2 (2 AFP) | | | | | | |

1. Prefix letter refers to the VDPV category: "cVDPV" = circulating VDPV, "iVDPV" = immunodeficiency-associated VDPV, "aVDPV" = ambiguous VDPV, "vVDPV" = pending.

Suffix number refers to the poliovirus serotype (types 1, 2 or 3).

2. Source of specimens could be AFP cases, contacts, non-AFP cases or environmental

3. Refers to year of last VDPV case, and aggregate total of VDPV cases for 2000-2009

4. Continuous excretion for 4 months; potential immunodeficient person.